Abstract: The present disclosure relates to a process and a device for winding a strand of hollow fiber membranes.

Abstract: An apparatus for extracorporeal treatment of blood (1) comprising a filtration unit (2), a blood withdrawal line (6), a blood return line (7), an effluent fluid line (13), a pre and/or post-dilution fluid line (15, 25) connected to the blood withdrawal line, and a dialysis fluid line. Pumps (17, 18, 21, 22, 27) act on the fluid lines for regulating the flow of fluid. A control unit (10) is configured to periodically calculate a new value for the patient fluid removal rate to be imposed on an ultrafiltration actuator in order to keep a predefined patient fluid removal rate across a reference time interval irrespective of machine down times.

Abstract: The present disclosure relates to methods for authorizing user access to medical equipment via an equipment user interface. In an example, the method comprises, storing an authority public key of an authority asymmetric key pair and providing, to a user via an equipment user interface, an authorization challenge indicative of an equipment public key of a temporary equipment asymmetric key pair generated in medical equipment. The method further comprises receiving from the equipment user interface, a response code comprising validity information encrypted using a shared key derivable from the authority private key of the authority asymmetric key pair and the provided equipment public key, and authorizing the user access to the medical equipment, upon the validity information decrypted using the same shared key but derived in the medical equipment using the stored authority public key and an equipment private key of the temporary equipment asymmetric key pair, being valid.

Abstract: A patient fluid removal compensation volume may be determined to make up for the patient fluid removal that does not occur during machine down times, and the patient fluid removal rate may be increased until the compensating volume is satisfied.

Abstract: The invention relates to a blood treatment device configured to dephosphorylate extracellular adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and/or lipopolysaccharide (LPS) in the blood of a patient in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix having alkaline phosphatase (AP) immobilized thereon. The invention further relates to an extracorporeal blood circuit comprising a blood treatment device of the invention and to the blood treatment device for use as a medicament or to methods of treating an infection, preferably a blood or systemic infection, such as sepsis, and/or for the treatment of sepsis-associated acute kidney injury (AKI).

Abstract: The present invention relates to removal of protein bound deleterious substances from an extracorporeal biological fluid by changing the affinity of the substance to the protein. The invention relates to the use of displacer substances for removal of deleterious substances. The present invention also relate to a method of removal, a system, a cleaning fluid comprising the displacer substances for removal of deleterious substances.

Abstract: A connector arrangement (10) for connecting to a fluid chamber (6) of a blood treatment unit (4) for extracorporeal blood treatments. The connector arrangement (10) includes a connector device (11) with a connector body (47) comprising a port opening (43) and an interior wall (50) defining a port space (39) designed to receive a first fluid port (8A) of the fluid chamber (6). The connector device (11) also incorporates a fluid path (35a) extending from the port space (39) to a first end opening (51) of the connector device (11), and an air path (36a) extending from the port space (39) to a second end opening (52) of the connector device (11), wherein the fluid path (35a) and the air path (36a) are separate paths. Also a system (1) for extracorporeal blood treatment including the connector arrangement (10) and a method for priming the fluid chamber (6).

Abstract: Extracorporeal blood treatment systems and methods to display graphical user interfaces displaying a plurality of fluids areas, each including a flow rate, and displaying adjustment notifications proximate one or more fluid areas. For example, when a user adjusts a flow rate to a limit, one or more notifications may be displayed proximate other flow rates that may be adjusted to modify the limit.

Abstract: A method of treating blood withdrawn from patient including: simultaneously withdrawing blood and infusing withdrawn blood from and to the patient by flowing the withdrawn blood through an extracorporeal dialysis circuit including a dialyzer having a semi-permeable dialysis membrane and a dialysate side adjacent the membrane; feeding a dialysate containing 1 to 5 mM total calcium and 2 to 8 mM citrate to the dialysate side of the dialyzer, and introducing an anticoagulation fluid including at least 8 mM citrate into the withdrawn blood upstream of the dialyzer.

Abstract: The present disclosure relates to a process for producing a filtration and/or diffusion device, e.g., a capillary dialyzer or an ultrafilter.

Abstract: The invention relates to a blood treatment device configured to remove anti-neutrophil cytoplasmic antibodies (ANCAs) from the blood or blood plasma of a person in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix, and wherein said matrix comprises a monomeric form of proteinase 3 (PR3). The invention further relates to an extra-corporeal blood circuit comprising a blood treatment device of the invention and to the blood treatment device for use as a medicament or to methods of treating a medical condition associated with ANCA.

Abstract: The present disclosure relates to a spinneret for producing hollow fiber membranes in a phase inversion process.

Abstract: The invention provides a first concentrate comprising lactate and calcium ions, said first concentrate having increased stability against precipitation at temperatures around +4° C., said first concentrate being useful for preparing a ready-to-use dialysis fluid by mixing said first concentrate with water and optionally a second concentrate comprising glucose, wherein that the lactate concentration Lconc (expressed in moles per litre, M) of the concentrate fulfills the conditions: a) Lconc>0.8 M; and b) Lconc<(1.9?0.4×Caready) M; and wherein Caready is the calcium concentration of the ready-to-use dialysis fluid expressed in millimoles per litre (mM).

Abstract: A monitoring system performs a method for detecting a disruption of a fluid connection between a first fluid containing system and a second fluid containing system. The monitoring system generates a monitoring signal which is representative of a fluid pressure in respect of the first fluid containing system and which is responsive to the disruption of the fluid connection, and a tracking signal which corresponds to and is more smoothed over time than the monitoring signal. The monitoring system further sets a detection range in a given relation to the tracking signal so that the detection range follows changes in the tracking signal, and detects a condition indicative of the disruption by comparing a current pressure value of the monitoring signal to the detection range. The monitoring system may be connected to or part of an apparatus for blood treatment and operable to detect a disconnection of an extracorporeal blood circuit from a vascular system of a patient, e.g.

Abstract: Methods and systems are provided for preparing a ready-to-use peritoneal dialysis fluid for peritoneal dialysis of a patient having a deficiency in potassium. The methods comprise mixing, immediately before administration to the patient, appropriate amounts of at least a first concentrate, a second concentrate, and a third concentrate with an appropriate amount of water to form a ready-to-use dialysis fluid. The first concentrate comprises glucose, has a pH of between 1.5 and 4, and is free of potassium ions; the second concentrate comprises a physiologically acceptable buffer and is free of potassium ions; and the third concentrate comprises the physiologically acceptable buffer and potassium ions.

Abstract: An extracorporeal blood treatment apparatus is provided comprising a filtration unit connected to a blood circuit and to a dialysate circuit; a control unit is configured for calculating a sodium concentration value for the blood; the estimation of the sodium concentration includes the sub-step of calculating the sodium concentration value as an algebraic sum of a main contribution term based on the isoconductive sodium concentrate and of an offset contribution term based on a concentration of at least a substance in the dialysis fluid chosen in the group including bicarbonate, potassium, acetate, lactate, citrate, magnesium, calcium, sulphate and phosphate.

Abstract: A monitoring device operates to monitor regional citrate anticoagulation (RCA) in a blood treatment system which is configured to administrate citrate to an extracorporeal blood circuit (10) upstream of a dialyzer (11) during a treatment session. At consecutive time steps during the treatment session, the monitoring device obtains a current measurement value of systemic ionized calcium (iCaSYS) or systemic total calcium (CaSYS), operates a predefined algorithm on the current measurement value to generate a current computation value that represents ionized calcium (iCa2, iCa3) in blood at a selected location (loc2, loc3) downstream or upstream of the dialyzer (11) in the extracorporeal blood circuit (10), and presents and/or evaluates the current computation value for assessment of the regional citrate anticoagulation. The need for conventional blood sampling and blood analysis upstream and/or downstream of the dialyzer, e.g. during CRRT, is thereby reduced significantly.

Abstract: An extracorporeal blood treatment apparatus is provided comprising a filtration unit connected to a blood circuit and to a dialysate circuit, a preparation device for preparing and regulating the composition of the dialysis fluid; a control unit is configured for setting a sodium concentration value for the dialysis fluid in the dialysis supply line at a set point based on the physician prescription; starting from the initial patient plasma conductivity, estimated at the beginning of the treatment, and based on the target plasma conductivity/sodium concentration which is equivalent to the dialysate conductivity/sodium concentration prescribed, the control unit determines the minimum constant gradient between dialysis fluid and plasma conductivity/concentration to be maintained during treatment to achieve the conductivity/concentration target in the patient plasma at the end of the session.

Abstract: The invention relates to a dispenser of a sealant for hemostasis comprising a container configured to receive a fibrinogen solution and an activation compartment being situated downstream of the container and comprising a functionalized support to which a coagulation factor, preferably thrombin, is immobilized, such that upon dispensing the fibrinogen solution it passes through the activation compartment, thereby generating and dispensing polymerizing fibrin as a sealant. The invention further relates to a support, exchangeable tip and a kit for the dispenser as well as to methods and uses of the dispenser or components thereof for dispensing a sealant to a desired site.

Abstract: Synthetic membranes for the removal, isolation, or purification of substances from a liquid. The membranes include at least one hydrophobic polymer and at least one hydrophilic polymer. 5-40 wt.-% of particles having an average particles size of between 0.1 and 15 ?m are entrapped. The membrane has a wall thickness of below 150 ?m. Methods for preparing the membranes in various geometries, and use of the membranes for the adsorption, isolation, and/or purification of substances from a liquid are explored.